|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
3D-CRT and IMRT groups had been analyzed by propensity score matching method, with sex, age, Karnofsky performance status, induction chemotherapy and tumor stage well matched.
|
31048664 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor tissue was obtained before initiating preop-CRT.
|
31516597 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A retrospective <i>in vivo</i> study compared tumour response to NA CRT in normal weight (n=53) versus overweight/obese patients (n=148).
|
31171903 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In the translational part of the study, we will evaluate the hypothesis that the baseline apparent diffusion coefficient (ADC) values of diffusion weighted MRI and its evolution 2 weeks after start of CRT, for the whole tumor as well as for intra-tumoral regions, is prognostic for residual tumor on the hysterectomy specimen.
|
30223802 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Patients undergoing extended CRT were more likely to harbor larger initial tumor size (p = 0.04), baseline nodal metastases (cN+; p < 0.001) and higher tumor location (p = 0.02).
|
29217398 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Using a novel approach to combination therapy, we show that sequential treatment with 5-FU or CRT followed by evofosfamide not only inhibits tumor growth of xenografts compared with 5-FU or CRT alone, but also significantly decreases the CC-IC fraction.
|
29476017 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We concluded that pretreatment tumor thickness is an independent predictor for pCR of stage II/III rectal adenocarcinoma to the neoadjuvant CRT.
|
27672742 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
LPA<sub>1/3</sub> signaling mediates tumor lymphangiogenesis through promoting CRT expression in prostate cancer.
|
30053596 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Logistic regression showed that post-CRT distance from the anal verge (OR =0.840, P = 0.022), post-CRT tumor size (OR = 0.565, P = 0.003), post-CRT circumferential extent of tumor (OR = 0.021, P < 0.001), pre-CRT CEA level (OR = 2.004, P = 0.033), and post-CRT CEA level (OR = 3.767, P = 0.038) were independently associated with pCR.
|
28978067 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Patients and Methods A secondary analysis was performed to compare IMRT with 3D-CRT in NRG Oncology clinical trial RTOG 0617, in which patients received concurrent chemotherapy of carboplatin and paclitaxel with or without cetuximab, and 60- versus 74-Gy radiation doses.
|
28034064 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Gene expression traits observed following long-course preoperative chemoradiotherapy in the discovery cohort suggested an increased abundance of natural killer cells in tumors that displayed a clinical response to CRT in a tumor regression grade-dependent manner.
|
28621318 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Additionally, we found that coadministration of IL2 DNA with pcDNA3-CRT/E7 modified the tumor microenvironment by decreasing the population of regulatory T cells and myeloid-derived suppressor cells relative to that of CTLs.
|
28492521 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Interaction testing found that CRT+S improved OS independently of age, comorbidity status, sex, race, and tumor stage.
|
28759121 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In xenograft experiments, CRT overexpression effectively inhibited the tumor growth.
|
28894229 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Preoperative chemoradiotherapy (pre-CRT) has been represented as the standard treatment for locally advanced rectal cancer (LARC), but large variations of tumor radiation response to CRT have been reported in the clinic.
|
27572313 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, understanding the molecular mechanisms underpinning tumour response and resistance to neo-CRT will contribute towards the identification of novel therapeutic targets for enhancing OAC sensitivity to CRT.
|
26221725 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Importantly, human liver metastases express higher CKB and SLC6A8 levels and reduced miR-551a/miR-483 levels relative to primary tumors.
|
25601461 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The KRAS WT is highly associated with tumor down-staging to cetuximab plus capecitabine-based CRT in patients with LARC.
|
22430888 |
2012 |